D.E. Shaw & Co’s enGene Therapeutics Warrants ENGNW Stock Holding History

D.E. Shaw & Co’s Portfolio ENGNW Stock Details ENGNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$275K	Hold	104,622	–	–	﹤0.01%	4110
2025 Q4	$314K	Hold	104,622	–	–	﹤0.01%	4124
2025 Q3	$75.3K	Hold	104,622	–	–	﹤0.01%	4380
2025 Q2	$70.1K	Hold	104,622	–	–	﹤0.01%	4151
2025 Q1	$67K	Hold	104,622	–	–	﹤0.01%	4046
2024 Q4	$88.9K	Hold	104,622	–	–	﹤0.01%	4176
2024 Q3	$209K	Hold	104,622	–	–	﹤0.01%	4136
2024 Q2	$145K	Hold	104,622	–	–	﹤0.01%	4128
2024 Q1	$544K	Sell	104,622 -100	-0.1%	-$305	﹤0.01%	3440
2023 Q4	$89K	Buy	+104,722	New	+$80.5K	﹤0.01%	3987

Other funds holding ENGNW

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return

TCM

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return

CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

ICM

Ionic Capital Management New York $1.37B AUM 48.26% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

D.E. Shaw & Co's ENGNW Position: Q1 2026 in Review

D.E. Shaw & Co held its enGene Therapeutics Warrants (ENGNW) position steady in Q1 2026 at 104,622 shares worth $275K. The position accounts for ﹤0.01% of the portfolio, ranked #4110.

D.E. Shaw & Co first reported a position in ENGNW in Q4 2023 and has held it in 10 quarters since. The position peaked at $544K in Q1 2024. 11 funds tracked by Wall St. Rank hold ENGNW as of Q1 2026.

D.E. Shaw & Co held 104,622 shares of enGene Therapeutics Warrants worth $275K as of Q1 2026.
D.E. Shaw & Co left its enGene Therapeutics Warrants share count unchanged in Q1 2026.
enGene Therapeutics Warrants made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #4110 holding.
D.E. Shaw & Co first reported a position in enGene Therapeutics Warrants in Q4 2023 and has held it in 10 quarters since.
D.E. Shaw & Co's enGene Therapeutics Warrants position peaked at $544K in Q1 2024.
11 funds tracked by Wall St. Rank held enGene Therapeutics Warrants as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.